WESTBURY, N.Y., Oct. 12, 2018 /PRNewswire/ -- Integrative Medicine of NY is one of the first clinical cancer facilities in the lower NY area to endorse and use the early detection and prevention lab test called IVYGENE. IMNY medical director Dr. Jesse Stoff is one of the first to support this new form of blood test by Laboratory for Advanced Medicine (LAM) that successfully confirms the presence of cancer as early as stage 1. It provides measurable data in the form of a score to make it easier to understand- while confirming the presence of cancer early, when it can be more easily managed and treated. The score can be used as a baseline to measure treatment effectiveness.
"IvyGene is similar to a liquid biopsy in terms of the technology... It is based on next-gen technology & sequencing," says Dr. Stoff. "For my purposes, I use this test for people who don't have signs of cancer because it takes about 10 years for cancer to go from a few cells into a destructive tumor. During that 10 year period, these abnormal cells are firing off pieces of genetic material into the blood stream that the IvyGene test is designed to pick up and act as an early warning where something is starting to grow someplace you need to pay attention to."
THE LAB-KIT TREND: PUBLICLY AFFORDABLE & ACCESSIBLE
A recent trend in testing kits commercially distributed to physicians or direct to consumers are changing the way patients are receiving treatment and how they are billed. Packaging lab tests through a portable transport kit is a most cost-effective and efficient way to increase public access to specialized lab service(s) by partnering with any clinic or practice. This streamlines the retrieval and delivery of acquired blood samples to the designated lab and greatly eliminates steps that impact "overhead" expenses.
Using highly advanced technology, LAM identifies specific gene targets in human DNA that correlate with cancer presence. Then, the IvyGene technology measures certain ratios at those specific gene targets. This results in a simple score that is either (a) elevated and consistent with the presence of cancer or (b) "normal" and not consistent with cancer presence.
"Our mission is to make cancer testing available and affordable for everyone. We work closely with thousands of physicians nationwide to provide early cancer confirmation and save lives sooner," states LAM representative Caleb Allen. "Unlike many genetic tests that use DNA to determine the propensity or possibility of developing cancer over time, the IvyGene test confirms actual disease presence at the time of testing."
CANCER OUTREACH TO FIRST RESPONDERS
A recent study from the International Association of Fire Fighters shows a significant percentage of firefighters diagnosed with cancer at some point during their lifetime, Dr. Stoff joined LAM to develop a public awareness project to bring genetic cancer testing such as the IvyGene test to the firefighter community. (Ref: www.firstresponderscancerresource.com). "This is my way of battling the elevated cancer cases from these brave men and women where their line of work often exposes them to all sorts of carcinogens and toxic situations."
To date, Dr. Jesse Stoff continues clinical research for advanced cancer treatment solutions. He invests heavily in cancer awareness, supporting cancer research and patient advocacy. He is also involved in writing and publishing articles and books about cancer treatment protocols & immunology while working full-time as the head clinical cancer care specialist in his private practice in Westbury, Long Island. For more information, visit www.imofny.com.
SOURCE Integrative Medicine of NY